Parabilis Medicines Analyst Price Targets - Benzinga

SPY752.77−0.21%QQQ682.33−0.43%BTC/USD76,880.18−0.60%DIA515.50−0.30%GLD360.31+0.29%TLT81.38+0.33%

Premium Services

Parabilis Medicines Inc

PBLSNASDAQ

Trade with Public

Trade with Public

$29.25

2.007.34%

Last update: Nov 3, 4:31 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Parabilis Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Parabilis Medicines (PBLS).

Price Target Range — 2 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$41Upside to Avg. PT+39.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 22, 2026	HC Wainwright & Co.	—	Initiate	Buy	$40
Jul 6, 2026	Leerink Partners	Andrew Berens	Initiate	Outperform	$40
Jul 6, 2026	Guggenheim	Michael Schmidt	Initiate	Buy	$40
Jul 6, 2026	B of A Securities	Tazeen Ahmad	Initiate	Buy	$45

Analyst Ratings News

PRO
HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40

HC Wainwright & Co. initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $40.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Parabilis Medicines with Outperform Rating, Announces Price Target of $40

Leerink Partners analyst Andrew Berens initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Outperform rating and announces Price Target of $40.

Benzinga Newsdesk

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed outlook on top stocks. See full analyst rating changes & buy/sell recommendations for PBLS stock on Benzinga.

Avi Kapoor

PRO
B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45

B of A Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $45.

Benzinga Newsdesk